Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

Clinigen acquires iQone Healthcare Holding
RNS
RNS Number : 0824C
Clinigen Group plc
26 September 2018

27 September 2018

Clinigen acquires Swiss based iQone Healthcare Holding
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has agreed to acquire iQone Healthcare Holding ('iQone'), a privately owned Swiss based speciality pharmaceutical business for an initial consideration of €7.5 million (£6.7 million) on a cash free, debt free basis.
iQone is based near Geneva with operations across Europe. It has medical and commercial operations in France, Germany, Italy, Spain and Switzerland. Its team has extensive experience in the set up and delivery of both Managed Access Programs and commercial solutions across Europe.
iQone adds capability to Clinigen's Unlicensed and Commercial divisions, whilst also offering the Group a platform to support and expand its activities in mainland Europe. It also provides iQone with resources and access to an extensive customer and product base to accelerate its growth.
Clinigen is acquiring iQone on a cash free, debt free basis for a total initial consideration of €7.5 million, made up of €5.0m in cash and €2.5m in new Clinigen shares, with an additional potential deferred consideration based on the achievement of certain future EBITDA targets.
The Group has also published today its year end results and announced that it is acquiring CSM - see separate announcements.
Shaun Chilton, Group Chief Executive Officer, Clinigen, said:
"Expanding our geographical footprint to support our activities in mainland Europe is a key benefit of this acquisition, along with the additional services it will offer our customers in Unlicensed Medicines. It also has the potential to drive growth in our owned Commercial Medicines portfolio.
"This acquisition coincides with our Full Year Results and the strategic acquisition of CSM, both announced earlier this morning. Today sees a significant strengthening in the Clinigen offering both through an increased global footprint, particularly in Europe, and across each of our three business divisions."
Laurent Massuyeau, Chief Executive Officer, iQone, said:
"We explored multiple strategic options which would allow iQone to grow and fulfil its potential. Clinigen is a recognised industry leader across the unlicensed and licensed medicine sectors. As both our companies share a common vision, we believe that being part of the Clinigen Group provides a compelling strategic fit and a strong growth potential."

Consideration detail
The €2.5m of initial share consideration will be satisfied through the issuance of 241,744 new Ordinary Shares in Clinigen (the "New Ordinary Shares") at an issue price of 925.13 pence per share. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8:00 a.m. on 9 October 2018. Completion of the acquisition is expected to take place on or about 9 October 2018. The Ordinary Shares will rank pari passu with the Group's existing ordinary shares in issue.
- Ends -

Proactive investor - Clinigen Group set for 77% upside according to RBC Capital
Share
15:21 15 Oct 2018
The company's prospects are boosted by recent acquisitions, and, according to RBC,more deals may follow.


Capital Network report here
RBC has a 1,470p price target
Clinigen Group PLC (LON:CLIN) shares could see some 77% upside to the current price, that’s according to RBC Capital, which rates the London listed life science company as a ‘top pick’.
RBC has a 1,470p price target, compared to the current price of around 830.3p.







“We believe acquisitions have positioned Clinigen as the No. 1 player in the ‘ethical’ supply of medications and, alongside existing products, this should lead to strong cash flow generation over the coming 5 years,” RBC analyst Nick Keher said in a note.
“With management aiming to double the number of products under its control and with the business model enhancing its product acquisition pipeline, we see this goal as likely.
READ: Clinigen raises £80mln to fund two new acquisitions
“We see further product acquisitions enhancing margins and promoting even faster earnings growth.”
Keher highlighted that further acquisitions are likely due to the company’s growing cash position and its desire to build a portfolio of ten products – and, such deals would represent a potential value catalyst for Clinigen shares.
Other possible catalysts identified by RBC include programme wins in the group’s Unlicensed Medicines division and/or upgrades created by the Quantum Pharma and CSM acquisitions.
“Clinigen trades at a material discount to its peer group but we think this discount will unwind as organic growth rates improve in FY19E,” the analyst said.
He added: “Our upside scenario values Clinigen at 1740p per share and is based upon the successful integration of recent acquisitions plus a return to growth of the CST and Unlicensed Medicines business, leading to forecast certainty and potential earnings upgrades.
“In such a scenario, we think Clinigen would hold a premium rating (c25x EPS) which we would apply to our FY20E estimates.”

In the Sunday Mail today -

THE SUNDAY TIMES
AIM-listed Clinigen specialises in supplying drugs to patients who cannot get access to them through normal channels, says Sarah Meddings in The Sunday Times Inside the City column.
Acting as a middleman, it can send a medicine that has been approved for use somewhere in the world to somewhere it has yet to get the green light — and add a mark-up for its trouble.
Demand for its services is set to surge in the next decade as patients, often in emerging markets, become more aware of the availability of life-saving treatments in different parts of the world and demand their doctor supplies them.
Since it listed on AIM in 2012, it has bought rival Idis in 2015 for £225million and Link Healthcare in the same year for £100million. In recent weeks, it returned to the acquisition trail, agreeing in September to buy CSM, a European specialist in packaging, labelling, warehousing and distribution. A second smaller deal to buy iQone, which specialises in oncology, for €7.5million (£6.6million), brought with it scientific expertise.
With increasing fears that a no-deal Brexit could cause chaos among medicine makers, Clinigen has been extremely smart. Shares have been volatile since the CSM deal was announced on September 26, falling 11.1 per cent the first day to 830p.
However, they have recovered to 902.5p, valuing the company at £1.2billion. And at 13 times expected full-year earnings, Clinigen is viewed as undervalued by analysts.
Verdict: Buy

Half Year trading update
RNS
RNS Number : 0648N
Clinigen Group plc
15 January 2019

15 January 2019

Half Year trading update

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2018.

Revenues increased by around 24% on a reported basis and by around 25% on a constant currency basis* compared to last year. Gross profit** increased by around 25% on a reported basis and by around 27% on a constant currency basis* in line with the Board's expectations.

The Group completed two corporate acquisitions, CSM and iQone, in October 2018 and two product acquisitions, Proleukin® and Imukin®, in July 2018. Both of the acquired businesses have performed well.

Shaun Chilton, Group Chief Executive Officer of Clinigen, said:

"The Unlicensed Medicines portfolio performed well as anticipated, starting a number of new programs, and we have diversified our Commercial Medicines portfolio with the purchase of two specialty medicines. We are already seeing the operational benefit of combining CTS with the clinical trial capabilities of the recently acquired CSM, which when combined with iQone, also acquired in October 2018, enhance our European and US infrastructure for the benefit of all our businesses.

"We are well positioned to deliver another good year of progress."

The Group expects to publish its interim results for the six months ended 31 December 2018 on Wednesday 27 February 2019.

* Constant currency is growth applying prior period's actual exchange rate to this period's result.
** Gross profit growth rates exclude the release of the fair valuation on inventory from business acquisitions.

- Ends -